Niagen Bioscience, Inc. (NAGE) Stock Forecast & Price Target
Niagen Bioscience, Inc. · NASDAQ
$3.29+0.06 (+1.86%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Niagen Bioscience, Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $11.00, so the covering firms are broadly aligned. The average target of $10.50 sits 219% above the current $3.29. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.06 next quarter toward $0.28 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Niagen Bioscience, Inc.
As of Jul, 2 of 2 firms rate NAGE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NAGE EPS & revenue forecast
EPS · NEXT QUARTER
$0.06
Range $0.03 – $0.08 · 6 analysts · +10% YoY
Next period, 6 analysts expect Niagen Bioscience, Inc. to earn $0.06 a share (range $0.03 – $0.08), versus $0.05 a year earlier. Full-year consensus is $0.22, growing to $0.28 the year after.
REVENUE · NEXT QUARTER
$37.1M
Range $34.8M – $39.0M · 6 analysts · +9% YoY
Revenue is expected to reach $37.1M (range $34.8M – $39.0M), +9.1% year-over-year. Full-year consensus is $141.4M, rising to $165.1M next year.
Top analysts covering Niagen Bioscience, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NAGE.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$11.00+234.3% to target
Overall win rate
37%
+ Follow
#2
Sean McGowan
Roth MKM · Rank #319
Buy
$12.00+264.7% to target
Overall win rate
28%
+ Follow
#3
Susan Anderson
Canaccord Genuity · Rank #352
Buy
$10.00+204.0% to target
Overall win rate
27%
+ Follow
NAGE stock forecast FAQ
What is NAGE's average 12-month price target?+
The 2 analysts with a live target average $10.50 for Niagen Bioscience, Inc. over the next 12 months, ranging from a $11.00 high to a $10.00 low.
Is NAGE stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NAGE?+
The Street-high target is $11.00 (HC Wainwright & Co.), and the Street-low is $10.00 (Canaccord Genuity). The average of all 2 active targets is $10.50.
How many Wall Street analysts cover NAGE?+
2 analysts have an active rating on Niagen Bioscience, Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NAGE?+
Among analysts who currently cover NAGE, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #249). Their current call is Buy with a $11.00 target.
What is Niagen Bioscience, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.06 per share (range $0.03 – $0.08) across 6 analysts. Full-year EPS is projected at $0.22, rising to $0.28 the following year.
How much revenue is Niagen Bioscience, Inc. expected to report next quarter?+
Consensus revenue is $37.1M (range $34.8M – $39.0M). Full-year revenue is projected at $141.4M, growing to $165.1M next year.
Have analysts been upgrading or downgrading NAGE lately?+
As of Jul, 2 of 2 firms rate NAGE a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NAGE calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
